Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Seres Therapeutics to Launch New Clinical Trial for Microbiome Drug

By Ryan Bushey | March 17, 2017

An experimental treatment for clostridium dificile infections is getting a second chance.

Seres Therapeutics will launch a new Phase 2 clinical trial for SER-109, an oral capsule being developed for patients with multiply recurrent Clostridium Difficile (C.Diff) infections. The therapy failed a clinical trial last year because the drug didn’t reduce the relative risk of C. Diff recurrence compared to the placebo, according to Xconomy.

Seres was able to restart these trials after consulting with the Food and Drug Administration.

Both organizations agreed that first experiment missed its mark because Seres missed the mark when it came diagnosing the C. diff infection status of patients throughout the study and gave subjects a suboptimal dose of SER-109, wrote FierceBiotech.

A number of measures will be implemented to ensure accurate results this time.

This new randomized, placebo-controlled analysis will involve an approximate 320 patients with the multiply recurrent form of the bacterial infection.

Investigators will administer a total SER-109 dose to patients in this arm over three days, which is an estimated 10-fold higher dose than the previous study. Volunteers will be evaluated over 24 weeks with the primary endpoint being a comparison between the recurrence rate for those receiving doses of the drugs versus placebo after an eight week period.

Stool sample diagnostics will be used to verify these findings as well.

The company will start this study later this year.


Filed Under: Drug Discovery

 

Related Articles Read More >

EpicentRx
A next-gen vaccine that could help end COVID-19 whack-a-mole 
Dotmatics
How Dotmatics aims to help reduce the drug discovery failure rate
Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50